Adial Pharmaceuticals, Inc. Unrecognized Tax Benefits, Income Tax Penalties Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Unrecognized Tax Benefits, Income Tax Penalties Expense of $690.03 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Income Taxes
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense · last filed 2024-04-01
- Adial Pharmaceuticals, Inc. unrecognized tax benefits, income tax penalties expense for the quarter ending 2023-12-31 was -$231.32K.
- Adial Pharmaceuticals, Inc. unrecognized tax benefits, income tax penalties expense for the quarter ending 2023-09-30 was -$380.14K.
- Adial Pharmaceuticals, Inc. unrecognized tax benefits, income tax penalties expense for fiscal 2023 was $690.03K.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 6 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$231.32K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$611.47K derived: sum of 2 quarters · filed 2024-04-01 | $690.03K 10-K · filed 2024-04-01 | |
| 2023-09-30 | -$380.14K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $921.36K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $1.30M 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |